Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment sector : Health services save search
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
Published: 2024-03-15 (Crawled : 20:00) - globenewswire.com
OPTN | $0.8951 -3.51% -3.64% 650K
|
Health Services
| Email alert
Add to watchlist
fda first xhance approved treatment
Chemotherapy Induced Peripheral Neuropathy Treatment Market Projected Strong Growth to $2.25 Billion by 2028 Amid Advancements in Cancer Treatment
Published: 2024-03-07 (Crawled : 00:00) - prnewswire.com
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: 1.41%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.62%
H: 0.0%
C: 0.0%
QDEL | News M | $39.09 2.17% 2.12% 1.1M
|
Health Technology
|
| O: 1.14%
H: 4.36%
C: 3.16%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.1%
H: 0.18%
C: -1.25%
cancer treatment growth market
Natera Presents New Signatera™ MRD Data Across Breast Cancer Treatment Settings at SABCS 2023
Published: 2023-12-06 (Crawled : 14:30) - biospace.com/
NTRA S | $85.275 -2.3% -2.35% 2.5M
|
Health Services
|
| O: 1.08%
H: 0.45%
C: -1.71%
breast cancer treatment sabcs
LHC Group Gets Center-Stage Treatment At UnitedHealth Group’s Investor Day
Published: 2023-11-30 (Crawled : 15:00) - lhcgroup.com
LHCG | News | $169.81 0.47% -0.03% 0
|
Health Services
| Email alert
Add to watchlist
day group treatment
Tigerlily Foundation and Labcorp Launch I AM INCLUDED Framework to Increase Clinical Trial Diversity, Accelerate Delivery of Innovative Cancer Treatments
Published: 2023-11-16 (Crawled : 12:00) - prnewswire.com
LH M | $201.48 1.02% 0.0% 770K
|
Health Services
|
| O: 0.49%
H: 0.0%
C: -0.1%
cancer trial
First results from PEGASUS trial reported at ESMO show promise for use of liquid biopsy to guide adjuvant treatment of colon cancer
Published: 2023-10-23 (Crawled : 09:00) - biospace.com/
GH M | $16.08 -3.54% -3.67% 1.9M
|
Health Services
|
| O: -0.51%
H: 5.33%
C: 1.88%
cancer treatment trial promise colon results show
First U.S. Patients Undergo Innovative Brain Cancer Treatment in New Clinical Trial at HCA Healthcare’s Johnston-Willis Hospital
Published: 2023-10-12 (Crawled : 15:30) - biospace.com/
HCA 4 | $305.11 2.73% -0.0% 1.5M
|
Health Services
|
| O: 0.25%
H: 0.36%
C: -3.97%
hospital cancer treatment trial
Burning Rock's minimal residual disease (MRD) product supports advancement in early-stage non-small cell lung cancer treatment, with results published in the Cancer Cell
Published: 2023-09-08 (Crawled : 03:00) - globenewswire.com
BNR | $0.72 -10.0% -11.11% 24K
|
Health Services
|
| O: -4.07%
H: 0.0%
C: -5.08%
lung disease cancer cell results
Biodesix Announces Two Presentations on Lung Cancer Treatment Guidance Tests at the IASLC 2023 World Lung Conference on Lung Cancer
Published: 2023-09-07 (Crawled : 13:00) - biospace.com/
BDSX | $1.24 -0.8% -0.81% 48K
|
Health Services
|
| O: 1.06%
H: 4.2%
C: -2.8%
lung conference world cancer treatment
Guardant Health Receives Regulatory Approval in Japan for Guardant360® CDx as Companion Diagnostic to ENHERTU® for Treatment of Non-Small Cell Lung Cancer Patients with HER2 Mutations
Published: 2023-09-05 (Crawled : 18:00) - biospace.com/
GH M | $16.08 -3.54% -3.67% 1.9M
|
Health Services
|
| O: 0.0%
H: 7.57%
C: 0.86%
guardant360 lung japan diagnostic health her2 approval cancer cell treatment companion
American Shared Hospital Services Subsidiary, GK Financing LLC, Introduces a New Dedicated Online Platform Redefining Access to Gamma Knife Radiosurgery Treatment Financing
Published: 2023-08-16 (Crawled : 12:00) - globenewswire.com
AMS | $2.99 2.75% 0.0% 6.3K
|
Health Services
|
| O: -1.44%
H: 7.27%
C: 1.46%
services hospital treatment platform
Burning Rock's precision oncology diagnostics product supports advancement in late-stage breast cancer treatment, with results published in the New England Journal of Medicine
Published: 2023-06-08 (Crawled : 05:00) - globenewswire.com
BNR | $0.72 -10.0% -11.11% 24K
|
Health Services
|
| O: -0.45%
H: 3.15%
C: 0.45%
breast cancer diagnostics results
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce FDA Approval of ELFABRIO® (pegunigalsidase alfa-iwxj) for the Treatment of Fabry Disease
Published: 2023-05-10 (Crawled : 10:00) - prnewswire.com
PLX | $1.15 1.77% -2.61% 450K
|
Health Services
|
| O: 3.42%
H: 2.65%
C: -2.65%
elfabrio fda rare disease approval treatment global
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease
Published: 2023-05-05 (Crawled : 12:00) - biospace.com/
PLX | $1.15 1.77% -2.61% 450K
|
Health Services
|
| O: 4.17%
H: 1.43%
C: -6.57%
prx-102 rare disease authorization treatment global
Guardant Health and Parker Institute for Cancer Immunotherapy (PICI) launch research collaboration to study connection between cancer biomarkers and immunotherapy treatment response
Published: 2023-04-25 (Crawled : 14:00) - biospace.com/
GH M | $16.08 -3.54% -3.67% 1.9M
|
Health Services
|
| O: -0.95%
H: 0.0%
C: -6.13%
institute health cancer treatment research immunotherapy collaboration response biomarkers study
OncoSec Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO™-EP in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment
Published: 2023-04-03 (Crawled : 11:00) - prnewswire.com
ONCS | $0.2772 25.59% 52M
|
Health Services
|
| O: -47.35%
H: 0.0%
C: 0.0%
ynote-695 keytruda melanoma treatment trial
Pharming announces US FDA approval of Joenja® (leniolisib) as the first and only treatment indicated for APDS
Published: 2023-03-24 (Crawled : 19:00) - prnewswire.com
NVTA | $0.019 0.0% 22M
|
Health Services
| Email alert
Add to watchlist
joenja fda approval treatment
Protalix BioTherapeutics Announces First Patient Dosed in First in Human Phase I Clinical Trial of PRX-115 for the Treatment of Severe Gout
Published: 2023-03-21 (Crawled : 11:00) - prnewswire.com
PLX | $1.15 1.77% -2.61% 450K
|
Health Services
|
| O: 1.0%
H: 1.49%
C: -0.99%
prx-115 treatment trial
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for Pegunigalsidase Alfa for Treatment of Fabry Disease
Published: 2023-02-24 (Crawled : 21:00) - biospace.com/
PLX | $1.15 1.77% -2.61% 450K
|
Health Services
|
| O: 0.59%
H: 15.2%
C: 6.43%
treatment rare global disease chmp positive
Guardant Health receives FDA approval for Guardant360® CDx as companion diagnostic for Menarini Group’s ORSERDU™ for treatment of patients with ESR1 mutations in ER+, HER2- advanced or metastatic breast cancer
Published: 2023-01-30 (Crawled : 13:00) - biospace.com/
GH M | $16.08 -3.54% -3.67% 1.9M
|
Health Services
|
| O: -1.0%
H: 0.96%
C: -0.93%
guardant360 treatment fda diagnostic breast health approval cancer esr1 mutation orserdu her2- her2 metastatic breast cancer
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.